Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
Conditions
Keywords
Moderate-Severe AD, Moderate-Severe Eczema, Eczema, Atopic Dermatitis
Brief summary
This is a randomized, double-blind, vehicle-controlled clinical study designed to evaluate the efficacy and safety of GX-03, a topically applied emollient, in adult subjects with moderate to severe eczema. Approximately 120 adult participants will be enrolled and randomized in a 1:1 ratio to receive either GX-03 or a petrolatum-based vehicle control for 8 consecutive weeks. Efficacy will be assessed using validated clinical outcome measures, including the Eczema Area and Severity Index (EASI), the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™), and the Peak Pruritus Numeric Rating Scale (PP-NRS). Safety will be evaluated through monitoring of treatment-emergent adverse events throughout the study period.
Detailed description
This Phase 2, randomized, double-blind, vehicle-controlled study will assess the efficacy and safety of GX-03 in adult individuals aged 18 to 70 years with moderate to severe eczema. Eligible participants will be randomly assigned to receive either GX-03 or a vehicle control, applied topically to affected areas at least twice daily for 8 weeks. The investigational product and vehicle will be identical in appearance and packaging to maintain blinding. Clinical efficacy will be evaluated at baseline and at Weeks 4 and 8. The primary efficacy endpoint is the change from baseline in Eczema Area and Severity Index (EASI) score at Weeks 4 and 8. Secondary efficacy endpoints include changes from baseline in vIGA-AD™ scores and Peak Pruritus Numeric Rating Scale (PP-NRS) scores at the same time points. Subject-reported outcomes and product preference questionnaires will also be collected as exploratory measures. Safety assessments will include the collection of spontaneous and solicited adverse events from the first application through the final study visit. Weekly telephone safety check-ins will be conducted during interim weeks, and adverse events will be assessed at all on-site visits. The study is expected to enroll sufficient subjects to ensure that at least 100 participants complete the full 8-week treatment period.
Interventions
COMBINATION_PRODUCTGX-03
Topical petrolatum-based ointment
OTHERVehicle
Ointment carrier
Sponsors
Turn Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Double-blinded, vehicle controlled, randomized
Intervention model description
The test article will be distributed to study participants and each participant instructed to use the test article on an area of interest. Each subject will be evaluated using the EASI severity scale, vIGA-AD™ scoring system, and PP-NRS score. Evaluations will occur at baseline and again after 4 and 8 weeks of daily use.
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Participants must meet all of the following criteria: * Adults aged 18 to 70 years, inclusive * Male or female subjects in good general health as determined by medical history * Presence of visible eczematous skin with disease severity consistent with moderate to severe eczema, as assessed by: * Eczema Area and Severity Index (EASI) and * Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) * Ability to read, understand, and provide written informed consent in English * Willingness and ability to comply with study procedures, including study visits and daily topical application * Agreement to use only the assigned study product on designated areas of interest for the duration of the study
Exclusion criteria
Individuals meeting any of the following criteria will be excluded: * Pregnant, breastfeeding, or planning pregnancy during the study * Presence of any skin condition or dermatologic disease that could interfere with study treatment or assessments * Use of systemic or topical immunosuppressive therapies, including corticosteroids, within 3 weeks prior to enrollment * Use of anti-inflammatory medications (e.g., topical steroids, ibuprofen, celecoxib); steroid nasal or ophthalmic drops are permitted * Use of topical medications at the test sites within 72 hours prior to enrollment * Damaged or altered skin at or near test sites (e.g., sunburn, tattoos, scars, uneven pigmentation) that could confound evaluations * Any medical condition that, in the investigator's judgment, places the subject at undue risk or compromises study integrity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Eczema Area and Severity (EASI) | Four and Eight Weeks | Change in EASI Over 4 and 8 Weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Investigator Global Assessment (IGA) | Four and Eight Weeks | Reduction in Investigator Global Assessment of -2 |
| Change in NRS Max Itch | Four and Eight Weeks | Change in Patient Itch Assessment |
Countries
United States
Contacts
CONTACTBarry Reece, MS
Outcome results
None listed